沙库巴曲缬沙坦在射血分数降低的心力衰竭患者中的真实世界使用情况分析

邵夏炎; 杨贝贝; 刘洪智; 徐予

doi:10.7619/jcmp.202002007

沙库巴曲缬沙坦在射血分数降低的心力衰竭患者中的真实世界使用情况分析

1. 河南大学人民医院心内科, 河南郑州, 450003;
2. 河南省人民医院心内科, 河南郑州, 450003

基金项目:

河南省科技发展计划(192112310063)

河南省医学科技攻关计划项目(2018020441)

详细信息

通讯作者:
徐予, E-mail: xyu66@sina.com

中图分类号: R541.6
计量
- 文章访问数: 376
- HTML全文浏览量: 94
- PDF下载量: 10
出版历程
- 收稿日期: 2019-11-12
- 网络出版日期: 2020-08-26
- 发布日期: 2020-08-26

Sacubitril/valsartan in heart failure patients with reduced ejection fraction: an analysis in the real-world prescription and treatment patterns

1. Department of Cardiology, The People's Hospital of Henan University, Zhengzhou, Henan, 450003;
2. Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003

摘要

摘要: 目的探讨沙库巴曲缬沙坦(ARNI)在射血分数降低的心力衰竭(HFrEF)患者中的真实世界实际使用情况。方法对254例使用ARNI的HFrEF患者进行6个月随访,根据随访时ARNI用量情况分为维持剂量组(n=148)、剂量增加组(n=37)、剂量减少或撤药组(n=69)。比较3组患者治疗前后的用药剂量情况、超声心动图参数、收缩压、实验室检查水平,分析影响ARNI滴定的相关因素。结果 5.1%的患者滴定至靶剂量。治疗6个月后,维持剂量组、剂量增加组的左室射血分数均较治疗前显著提高(△(-overx)=7.6%、12.1%, P<0.01), 收缩压显著降低(△(-overx)=-16.4 mmHg、-7.6 mmHg, P<0.05)。多因素Logistic 回归分析显示,再住院(OR=3.89, 95%CI为1.66~9.13, P<0.01)是ARNI剂量滴定的独立预测因子。结论大部分使用ARNI患者维持在低于靶剂量水平,心功能虽然得到明显改善,但仍错失可增加药物滴定的机会,并未最佳获益。目前ARNI滴定往往通过再住院实现,因此需加强心衰患者的教育和随访管理。
- 沙库巴曲缬沙坦 /
- 心力衰竭 /
- 滴定 /
- 随访管理 /
- 射血分数降低的心力衰竭
Abstract: Objective To explore the real-world prescription and treatment patterns of sacubitril/valsartan(ARNI)in heart failure patients with reduced ejection fraction(HFrEF). Methods A total of 254 consecutive patients diagnosed as HFrEF and treated by ARNI were followed up for 6 months. According to the amount of ARNI during follow-up, the patients were divided into maintenance dose group(n=148), dose increase group(n=37)and dose reduction or withdrawal group(n=69). The dosage, echocardiographic parameters, systolic blood pressure and laboratory test level of three groups were compared before and after treatment, and the related influencing factors for ARNI titration were analyzed. Results 5.1% of patients titrated to the target dose. After 6 months of treatment, the left ventricular ejection fraction(LVEF)in the maintenance dose group and the dose increase group was significantly higher than that before treatment(△(-overx)=7.6%, 12.1%, P<0.01), and systolic blood pressure significantly reduced than those before treatment(△(-overx)=-16.4 mmHg, -7.6 mmHg, P<0.05). Multivariate Logistic regression analysis showed that readmission(OR=3.89, 95% CI=1.66~9.13, P<0.01)was an independent predictor of ARNI dose titration. Conclusion Most of the patients use ARNI at a maintenance level below the target dose level. Although the cardiac function has been improved significantly, the patients still miss the opportunity to increase the drug titration, and do not get the best benefit. At present, ARNI titration is often achieved through - readmission, so it is necessary to strengthen the education and follow-up management of patients with heart failure.
- sacubitril/valsartan /
- heart failure /
- titration /
- follow-up management /
- heart failure with reduced ejection fraction

HTML全文

参考文献(15)

Anand I. Stable but progressive nature of heart failure: considerations for primary care physicians[J]. Am J Cardiovasc Drugs, 2018, 18(5): 333-345.

Ibrahim N E, McCarthy C P, Shrestha S, et al. Effect of neprilysin inhibition on various natriuretic peptide assays[J]. J Am Coll Cardiol, 2019, 73(11): 1273-1284.

McMurray J J, Packer M, Desai A S, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11): 993-1004.

Ponikowski P, Voors A A, Anker S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J]. Eur J Heart Fail, 2016, 18(8): 891-975.

Zhao Y, Ma R X, Yu X R, et al. AHU377+Valsartan(LCZ696)modulates renin-angiotensin system(RAS)in the cardiac of female spontaneously hypertensive rats compared with valsartan[J]. J Cardiovasc Pharmacol Ther, 2019, 24(5): 450-459.

Nishimura R A, Otto C M, Bonow R O, et al. 2014 Aha/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2014, 63(22): e57-e185.

Du A X, Westerhout C M, McAlister F A, et al. Titration and tolerability of sacubitril/valsartan for patients with heart failure in clinical practice[J]. J Cardiovasc Pharmacol, 2019, 73(3): 149-154.

Diamant M J, Virani S A, MacKenzie W J, et al. Medical therapy doses at hospital discharge in patients with existing and de novo heart failure[J]. ESC Heart Fail, 2019, 6(4): 774-783.

Zhang Y H, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure(China-HF)registry[J]. J Card Fail, 2017, 23(12): 868-875.

Gan TY, Liu NN, Zhang YH, et al. A Knowledge Survey on Heart Failure Guidelines in Physicians[J]. Chinese Circulation Journal, 2017, 32(10): 952-955.

Martens P, Lambeets S, Lau C W, et al. Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions[J]. Acta Cardiol, 2019, 74(2): 115-122.

Bhagat A A, Greene S J, Vaduganathan M, et al. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization[J]. JACC Heart Fail, 2019, 7(1): 1-12.

Greene S J, Fonarow G C, Vaduganathan M, et al. The vulnerable phase after hospitalization for heart failure[J]. Nat Rev Cardiol, 2015, 12(4): 220-229.

Laflamme, Vachon A, Gilbert S, et al. Usefulness of a titration algorithm for de novo users of sacubitril/valsartan in a tertiary centre heart failure clinic[J]. Cardiovasc J Afr, 2018, 29(6): 352-356.

Anderson S L, Marrs J C. A review of the role of the pharmacist in heart failure transition of care[J]. Adv Ther, 2018, 35(3): 311-323.